Synergistic protein secretion by mesenchymal stromal cells seeded in 3D scaffolds and circulating leukocytes in physiological flow

Biomaterials

Volumn 35, Issue 33, 2014, Pages 9100-9113

  Ballotta, Virginia ^a   Smits, Anthal I P M ^a   Driessen Mol, Anita ^a   Bouten, Carlijn V C ^a   Baaijens, Frank P T ^a  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

Cell signaling; Chemotaxis; Co culture; Fibroblast growth factor; Monocytes; Shear stress

Indexed keywords

BIOCHEMISTRY; CELL SIGNALING; CELLS; CYTOLOGY; GENE EXPRESSION; PHYSIOLOGY; PROTEINS; PULSATILE FLOW; SHEAR FLOW; SHEAR STRESS;

CHEMOTAXIS; COCULTURE; FIBROBLAST GROWTH FACTOR; HUMAN PERIPHERAL BLOOD; JUXTACRINE SIGNALING; MESENCHYMAL STROMAL CELLS; MONOCYTES; PHYSIOLOGICAL FLOW;

SCAFFOLDS (BIOLOGY);

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CHEMOKINE RECEPTOR CXCR4; FIBROBLAST GROWTH FACTOR; POLYCAPROLACTONE; VASCULOTROPIN; CCL2 PROTEIN, HUMAN; CXCL12 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR 2; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYESTER; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CHEMOTAXIS; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKOCYTE; MESENCHYMAL STROMA CELL; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SECRETION; SHEAR STRESS; SIGNAL TRANSDUCTION; TISSUE SCAFFOLD; UPREGULATION; ADIPOSE TISSUE; CELL CULTURE; CHEMISTRY; CYTOLOGY; MONONUCLEAR CELL; PHYSIOLOGY; PROCEDURES; SECRETION (PROCESS); TISSUE ENGINEERING; WOUND HEALING;

ADIPOSE TISSUE; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINE CXCL12; FIBROBLAST GROWTH FACTOR 2; HUMANS; LEUKOCYTES, MONONUCLEAR; MESENCHYMAL STROMAL CELLS; POLYESTERS; TISSUE ENGINEERING; TISSUE SCAFFOLDS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84906785104     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.07.042     Document Type: Article

References (61)

1. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
2. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
3. Shi Y., Su J., Roberts A.I., Shou P., Rabson A.B., Ren G. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 2012, 33:136-143.
4. Caplan A.I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. JCell Physiol 2007, 213:341-347.
5. Le Blanc K., Rasmusson I., Sundberg B., Götherström C., Hassan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
6. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
7. Fisher S.A., Dorée C., Brunskill S.J., Mathur A., Martin-Rendon E. Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: a systematic review and meta-analysis. PLoS One 2013, 8:e64669.
8. Vincentelli A., Wautot F., Juthier F., Fouquet O., Corseaux D., Marechaux S., et al. Invivo autologous recellularization of a tissue-engineered heart valve: are bone marrow mesenchymal stem cells the best candidates?. JThorac Cardiovasc Surg 2007, 134:424-432.
9. Matsumura G., Miyagawa-Tomita S., Shin'oka T., Ikada Y., Kurosawa H. First evidence that bone marrow cells contribute to the construction of tissue-engineered vascular autografts invivo. Circulation 2003, 108:1729-1734.
10. Matsumura G., Ishihara Y., Miyagawa-Tomita S., Ikada Y., Matsuda S., Kurosawa H., et al. Evaluation of tissue-engineered vascular autografts. Tissue Eng 2006, 12:3075-3083.
11. Hibino N., Shin'oka T., Matsumura G., Ikada Y., Kurosawa H. The tissue-engineered vascular graft using bone marrow without culture. JThorac Cardiovasc Surg 2005, 129:1064-1070.
12. Weber B., Dijkman P.E., Scherman J., Sanders B., Emmert M.Y., Grünenfelder J., et al. Off-the-shelf human decellularized tissue-engineered heart valves in a non-human primate model. Biomaterials 2013, 34:7269-7280.
13. Emmert M.Y., Weber B., Behr L., Frauenfelder T., Brokopp C.E., Grünenfelder J., et al. Transapical aortic implantation of autologous marrow stromal cell-based tissue-engineered heart valves: first experiences in the systemic circulation. JACC Cardiovasc Interv 2011, 4:822-823.
14. Emmert M.Y., Weber B., Wolint P., Behr L., Sammut S., Frauenfelder T., et al. Stem cell-based transcatheter aortic valve implantation: first experiences in a pre-clinical model. JACC Cardiovasc Interv 2012, 5:874-883.
15. Hibino N., McGillicuddy E., Matsumura G., Ichihara Y., Naito Y., Breuer C., et al. Late-term results of tissue-engineered vascular grafts in humans. JThorac Cardiovasc Surg 2010, 139. 431-436.e2.
16. Shin'oka T., Matsumura G., Hibino N., Naito Y., Watanabe M., Konuma T., et al. Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. JThorac Cardiovasc Surg 2005, 129:1330-1338.
17. Matsumura G., Hibino N., Ikada Y., Kurosawa H., Shin'oka T. Successful application of tissue engineered vascular autografts: clinical experience. Biomaterials 2003, 24:2303-2308.
18. Roh J.D., Sawh-Martinez R., Brennan M.P., Jay S.M., Devine L., Rao D., et al. Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc Natl Acad Sci U S A 2010, 107:4669-4674.
19. Colazzo F., Sarathchandra P., Smolenski R.T., Chester A.H., Tseng Y.-T., Czernuszka J.T., et al. Extracellular matrix production by adipose-derived stem cells: implications for heart valve tissue engineering. Biomaterials 2011, 32:119-127.
20. Charoenpanich A., Wall M.E., Tucker C.J., Andrews D.M.K., Lalush D.S., Loboa E.G. Microarray analysis of human adipose-derived stem cells in three-dimensional collagen culture: osteogenesis inhibits bone morphogenic protein and Wnt signaling pathways, and cyclic tensile strain causes upregulation of proinflammatory cytokine regulators. Tissue Eng Part A 2011, 17:2615-2627.
21. Ballotta V., Driessen-Mol A., Bouten C.V.C., Baaijens F.P.T. Strain-dependent modulation of macrophage polarization within scaffolds. Biomaterials 2014, 35:4919-4928.
22. Smits A.I.P.M., Ballotta V., Driessen-Mol A., Bouten C.V.C., Baaijens F.P.T. Shear flow affects selective monocyte recruitment into MCP-1-loaded scaffolds. JCell Mol Med 2014, [in press]. 10.1111/jcmm.12330.
23. Wisse E., Govaert L.E., Meijer H.E.H., Meijer E.W. Unusual tuning of mechanical properties of thermoplastic elastomers using supramolecular fillers. Macromolecules 2006, 39:7425-7432.
24. Mol A., van Lieshout M.I., Dam-de Veen C.G., Neuenschwander S., Hoerstrup S.P., Baaijens F.P.T., et al. Fibrin as a cell carrier in cardiovascular tissue engineering applications. Biomaterials 2005, 26:3113-3121.
25. Boerboom R.A., Rubbens M.P., Driessen N.J.B., Bouten C.V.C., Baaijens F.P.T. Effect of strain magnitude on the tissue properties of engineered cardiovascular constructs. Ann Biomed Eng 2008, 36:244-253.
26. Smits A.I.P.M., Driessen-Mol A., Bouten C.V.C., Baaijens F.P.T. Amesofluidics-based test platform for systematic development of scaffolds for in situ cardiovascular tissue engineering. Tissue Eng Part C Methods 2012, 18:475-485.
27. Shantsila E., Wrigley B., Tapp L., Apostolakis S., Montoro-Garcia S., Drayson M.T., et al. Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. JThromb Haemost 2011, 9:1056-1066.
28. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. JLeukoc Biol 2007, 81:584-592.
29. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3. RESEARCH0034.
30. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
31. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation invitro and prolong skin graft survival invivo. Exp Hematol 2002, 30:42-48.
32. Weber B., Scherman J., Emmert M.Y., Gruenenfelder J., Verbeek R., Bracher M., et al. Injectable living marrow stromal cell-based autologous tissue engineered heart valves: first experiences with a one-step intervention in primates. Eur Heart J 2011, 32:2830-2840.
33. Ren G., Zhang L., Zhao X., Xu G., Zhang Y., Roberts A.I., et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2:141-150.
34. Groh M.E., Maitra B., Szekely E., Koç O.N. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005, 33:928-934.
35. Maggini J., Mirkin G., Bognanni I., Holmberg J., Piazzón I.M., Nepomnaschy I., et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 2010, 5. e9252.
36. Freytes D.O., Kang J.W., Marcos-Campos I., Vunjak-Novakovic G. Macrophages modulate the viability and growth of human mesenchymal stem cells. JCell Biochem 2013, 114:220-229.
37. Kwon Y.W., Heo S.C., Jeong G.O., Yoon J.W., Mo W.M., Lee M.J., et al. Tumor necrosis factor-α-activated mesenchymal stem cells promote endothelial progenitor cell homing and angiogenesis. Biochim Biophys Acta 2013, 1832:2136-2144.
38. Melief S.M., Geutskens S.B., Fibbe W.E., Roelofs H. Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6. Haematologica 2013, 98:888-895.
39. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, 8:726-736.
40. Puissant B., Barreau C., Bourin P., Clavel C., Corre J., Bousquet C., et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005, 129:118-129.
41. Ren G., Zhao X., Zhang L., Zhang J., L'Huillier A., Ling W., et al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. JImmunol 2010, 184:2321-2328.
42. Kim J., Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009, 37:1445-1453.
43. Hanson S.E., King S.N., Kim J., Chen X., Thibeault S.L., Hematti P. The effect of mesenchymal stromal cell-hyaluronic acid hydrogel constructs on immunophenotype of macrophages. Tissue Eng Part A 2011, 17:2463-2471.
44. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
45. Hatzistergos K.E., Quevedo H., Oskouei B.N., Hu Q., Feigenbaum G.S., Margitich I.S., et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 2010, 107:913-922.
46. Kinnaird T., Stabile E., Burnett M.S., Shou M., Lee C.W., Barr S., et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004, 109:1543-1549.
47. Askari A.T., Unzek S., Popovic Z.B., Goldman C.K., Forudi F., Kiedrowski M., et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003, 362:697-703.
48. Sordi V., Malosio M.L., Marchesi F., Mercalli A., Melzi R., Giordano T., et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005, 106:419-427.
49. Chen L., Tredget E.E., Wu P.Y.G., Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008, 3. e1886.
50. Willenborg S., Lucas T., van Loo G., Knipper J., Krieg T., Haase I., et al. CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. Blood 2012, 120:613-625.
51. Schmidt A., Ladage D., Schinköthe T., Klausmann U., Ulrichs C., Klinz F.-J., et al. Basic fibroblast growth factor controls migration in human mesenchymal stem cells. Stem Cells 2006, 24:1750-1758.
52. Abe M., Yokoyama Y., Ishikawa O. Apossible mechanism of basic fibroblast growth factor-promoted scarless wound healing: the induction of myofibroblast apoptosis. Eur J Dermatol 2012, 22:46-53.
53. Shireman P.K., Contreras-Shannon V., Ochoa O., Karia B.P., Michalek J.E., McManus L.M. MCP-1 deficiency causes altered inflammation with impaired skeletal muscle regeneration. JLeukoc Biol 2007, 81:775-785.
54. Capoccia B.J., Gregory A.D., Link D.C. Recruitment of the inflammatory subset of monocytes to sites of ischemia induces angiogenesis in a monocyte chemoattractant protein-1-dependent fashion. JLeukoc Biol 2008, 84:760-768.
55. Volpe S., Cameroni E., Moepps B., Thelen S., Apuzzo T., Thelen M. CCR2 acts as scavenger for CCL2 during monocyte chemotaxis. PLoS One 2012, 7. e37208.
56. Segers V.F.M., Lee R.T. Biomaterials to enhance stem cell function in the heart. Circ Res 2011, 109:910-922.
57. Yoo K.H., Jang I.K., Lee M.W., Kim H.E., Yang M.S., Eom Y., et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol 2009, 259:150-156.
58. Williams A.R., Hare J.M. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011, 109:923-940.
59. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102:3837-3844.
60. Spaeth E.L., Dembinski J.L., Sasser A.K., Watson K., Klopp A., Hall B., et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4. e4992.
61. Ren C., Geng R.-L., Ge W., Liu X.-Y., Chen H., Wan M.-R., et al. An observational study of autologous bone marrow-derived stem cells transplantation in seven patients with nervous system diseases: a 2-year follow-up. Cell Biochem Biophys 2014, 69:179-187.